The decision by Anvisa follows a ruling by the Superior Court of Justice ordering the federal government to establish clear regulations for marijuana cultivation strictly for medicinal and pharmaceutical use. One allows companies to cultivate marijuana in secure, controlled environments, with plants limited to a maximum THC concentration of 0.3%. Another establishes rules for scientific research, allowing cultivation without THC limits and granting authorization to institutions rather than individual research projects. A third introduces an experimental model for patient associations, which will be selected through a public call and supervised directly by the agency. Figueiredo noted that of the roughly 350 cannabis patient associations in Brazil, only about 25 previously had court authorization to cultivate marijuana, underscoring the level of legal uncertainty that existed.